Name
Syndax Pharmaceuticals
Company Description
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com.
Website
Product Categories (5)
Pharmaceutical
Conquer Cancer, the ASCO Foundation Donor
Yes
First Time Exhibitor
Yes
Phone (If provided, phone will display online and in-print)
781-419-1400
Address
Waltham, MA
United States
United States
Twitter
Recognition
